Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 10/20 | 0.45 |
| ▸ | PRKDC | P78527 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TLR2 | O60603 | 1/20 | 0.35 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.35 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.35 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.35 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.35 |
| ▸ | ABAT | P80404 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16078299 | 0.87 | ERN1 (0.41) | ERN1PRKDCALDH1A1TSHRTDP1 | |
| SCHEMBL18297672 | 0.86 | ERN1 (0.40) | ERN1PRKDCALDH1A1TSHRTDP1 | |
| SCHEMBL15065874 | 0.86 | ERN1 (0.53) | ERN1PRKDCALDH1A1TDP1CA12 | |
| SCHEMBL31627517 | 0.86 | ERN1 (0.40) | ERN1PRKDCALDH1A1TSHRTDP1 | |
| SCHEMBL4981553 | 0.86 | ERN1 (0.40) | ERN1PRKDCALDH1A1TSHRTDP1 | |
| SCHEMBL23641164 | 0.86 | ERN1 (0.40) | ERN1PRKDCALDH1A1TSHRTDP1 | |
| SCHEMBL16237591 | 0.85 | ERN1 (0.37) | ERN1PRKDCALDH1A1TSHRTDP1 | |
| SCHEMBL16072968 | 0.82 | ERN1 (0.38) | ERN1PRKDCALDH1A1TSHRTDP1 | |
| SCHEMBL29935710 | 0.76 | ALDH1A1 (0.47) | ERN1PRKDCALDH1A1TSHRTDP1 | |
| SCHEMBL23536227 | 0.74 | ALDH1A1 (0.45) | ERN1PRKDCALDH1A1TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112574175-B | Quinoline compound, preparation method and application thereof | 南京长澳医药科技有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-107922401-B | 4-hydroxy-3- (heteroaryl) pyridin-2-one APJ agonists for the treatment of cardiovascular disorders | 百时美施贵宝公司 | 2021-04-16 | — | — | CN | disclosed |
| WO-2021057190-A1 | QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海阳帆医药科技有限公司 | 2021-04-01 | — | — | WO | disclosed |
| CN-112574175-A | Quinoline compound, preparation method and application thereof | 上海阳帆医药科技有限公司 | 2021-03-30 | — | — | CN | disclosed |
| US-10822326-B2 | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-10822326-B2 | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2020-11-03 | — | — | US | disclosed |
| US-20200190058-A1 | SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-06-18 | — | — | US | disclosed |
| US-20200190058-A1 | SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-06-18 | — | — | US | disclosed |
| EP-2797597-B1 | SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | GLOBAL BLOOD THERAPEUTICS INC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20070082909-A1 | Acyclic Ikur inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-12 | — | — | US | disclosed |
| EP-1399444-B1 | NOVEL HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING SAME AND USE THEREOF AS MEDICINES, IN PARTICULAR AS ANTI-BACTERIAL AGENTS | NOVEXEL (FR) | 2007-04-11 | — | — | EP | disclosed |
| WO-2007030582-A2 | ACYCLIC IKUR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007030582-A2 | ACYCLIC IKUR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-15 | — | — | WO | disclosed |
| US-20050245505-A1 | Novel heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents | ENTASIS THERAPEUTICS LIMITED (GB) | 2005-11-03 | — | — | US | disclosed |
| CN-1169792-C | Substituted vinylpyridine derivatives and medicaments containing them | ������ҩ��ʽ���� | 2004-10-06 | — | — | CN | disclosed |
| EP-0882714-B1 | SUBSTITUTED VINYLPYRIDINE DERIVATIVES AND DRUGS CONTAINING THE SAME | SS PHARMACEUTICAL CO (JP) | 2004-03-03 | — | — | EP | disclosed |
| US-5935977-A | PHOSPHODIESTERASE IV INHIBITORS, TUMOR NECROSIS FACTOR-ALPHA PRODUCTION INHIBITORS; TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES | SS PHARMACEUTICAL CO., LTD. (JP) | 1999-08-10 | — | — | US | disclosed |
| CN-1206407-A | Substituted vinylpyridine derivatives and medicaments containing them | SS PHARMACEUTICAL CO (JP) | 1999-01-27 | — | — | CN | disclosed |
| EP-0882714-A1 | SUBSTITUTED VINYLPYRIDINE DERIVATIVES AND DRUGS CONTAINING THE SAME | SS Pharmaceutical Co., Ltd. (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082909-A1 | Acyclic Ikur inhibitors | KCNH2, KCNJ2, KCNH3 | ERN1 362/4885PRKDC 1382/4885ALDH1A1 1792/4885 |
| US-20050245505-A1 | Novel heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents | FDPS, MRPL21, DHPS | ERN1 2378/4885PRKDC 2782/4885ALDH1A1 1565/4885 |
| US-20200190058-A1 | SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | HBB, HBG2, MB | ERN1 4304/4885PRKDC 2920/4885ALDH1A1 43/4885 |
| US-10822326-B2 | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation | HBB, HBG2, MB | ERN1 4304/4885PRKDC 2920/4885ALDH1A1 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.